Kymera Therapeutics Future Growth

Future criteria checks 2/6

Kymera Therapeutics's earnings are forecast to decline at 4.8% per annum while its annual revenue is expected to grow at 25.2% per year. EPS is expected to decline by 0.09% per annum. Return on equity is forecast to be -62.9% in 3 years.

Key information

-4.8%

Earnings growth rate

-0.09%

EPS growth rate

Biotechs earnings growth	28.1%
Revenue growth rate	25.2%
Future return on equity	-62.9%
Analyst coverage	Good
Last updated	24 Oct 2024

Recent future growth updates

Analysts Are Upgrading Kymera Therapeutics, Inc. (NASDAQ:KYMR) After Its Latest Results

Aug 11

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Released Earnings Last Week And Analysts Lifted Their Price Target To US$47.43

Feb 25

Recent updates

Kymera's Protein Degradation Technology: A Promising Bet For Long-Term Biotech Investors

Oct 06

Analysts Are Upgrading Kymera Therapeutics, Inc. (NASDAQ:KYMR) After Its Latest Results

Aug 11

Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) 27% Share Price Surge Not Quite Adding Up

Jul 14

Shareholders Will Probably Hold Off On Increasing Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) CEO Compensation For The Time Being

Jun 12

We Think Kymera Therapeutics (NASDAQ:KYMR) Can Easily Afford To Drive Business Growth

May 03

Kymera Therapeutics: Advancing Into Phase 2 With Partner Sanofi - I Still Have Faith

Mar 21

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Released Earnings Last Week And Analysts Lifted Their Price Target To US$47.43

Feb 25

Optimistic Investors Push Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Up 39% But Growth Is Lacking

Feb 17

Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Shares Climb 33% But Its Business Is Yet to Catch Up

Dec 29

We Think Kymera Therapeutics (NASDAQ:KYMR) Needs To Drive Business Growth Carefully

Nov 06

Industry Analysts Just Made A Substantial Upgrade To Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Revenue Forecasts

Aug 31

Here's Why We're Not Too Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Situation

Aug 04

Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Share Price Not Quite Adding Up

May 21

We're Hopeful That Kymera Therapeutics (NASDAQ:KYMR) Will Use Its Cash Wisely

Apr 16

Companies Like Kymera Therapeutics (NASDAQ:KYMR) Are In A Position To Invest In Growth

Dec 28

Kymera KT-333 gets FDA orphan drug status for blood cancer subtype

Sep 15

Earnings and Revenue Growth Forecasts

NasdaqGM:KYMR - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	72	-289	-223	-186	15
12/31/2025	67	-272	-144	-172	18
12/31/2024	59	-214	-185	-160	17
6/30/2024	89	-158	-138	-106	N/A
3/31/2024	79	-155	-136	-98	N/A
12/31/2023	79	-147	-137	-103	N/A
9/30/2023	47	-167	-174	-150	N/A
6/30/2023	52	-158	-169	-153	N/A
3/31/2023	47	-159	-163	-157	N/A
12/31/2022	47	-155	-156	-153	N/A
9/30/2022	46	-154	-155	-152	N/A
6/30/2022	57	-139	-157	-155	N/A
3/31/2022	64	-124	-148	-146	N/A
12/31/2021	73	-100	-131	-129	N/A
9/30/2021	70	-79	-113	-111	N/A
6/30/2021	65	-58	54	58	N/A
3/31/2021	49	-48	69	77	N/A
12/31/2020	34	-55	79	88	N/A
9/30/2020	23	-53	90	97	N/A
6/30/2020	9	-57	-52	-47	N/A
3/31/2020	6	-52	-17	-15	N/A
12/31/2019	3	-41	17	18	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: KYMR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: KYMR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: KYMR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: KYMR's revenue (25.2% per year) is forecast to grow faster than the US market (8.9% per year).

High Growth Revenue: KYMR's revenue (25.2% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: KYMR is forecast to be unprofitable in 3 years.

Kymera Therapeutics Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Analysts Are Upgrading Kymera Therapeutics, Inc. (NASDAQ:KYMR) After Its Latest Results

Consensus EPS estimates upgraded to US$2.90 loss, revenue downgraded

Price target increased by 7.0% to US$51.07

Consensus revenue estimates increase by 45%

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Released Earnings Last Week And Analysts Lifted Their Price Target To US$47.43

Price target increased by 8.3% to US$43.00

Recent updates

Kymera Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

Kymera Therapeutics, Inc. Announces Dosing of First Participant in Phase 1 Clinical Trial of KT-621, a First-In-Class Oral STAT6 Degrader, for the Treatment of TH2 Immuno-Inflammatory Diseases

Kymera Therapeutics, Inc. to Report Q3, 2024 Results on Oct 31, 2024

Kymera Therapeutics, Inc. Announces FDA Clearance of Investigational New Drug Application for KT-621, A First-In-Class, Oral Stat6 Degrader

Kymera's Protein Degradation Technology: A Promising Bet For Long-Term Biotech Investors

Kymera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $224.999632 million.

Kymera Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

Analysts Are Upgrading Kymera Therapeutics, Inc. (NASDAQ:KYMR) After Its Latest Results

Kymera Therapeutics, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) 27% Share Price Surge Not Quite Adding Up

Kymera Therapeutics, Inc. Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy

Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of Stat3 Degrader Kt-333 At Eha Annual Meeting

Shareholders Will Probably Hold Off On Increasing Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) CEO Compensation For The Time Being

Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting

Kymera Therapeutics, Inc. Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting

Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of Stat3 Degrader KT-333 At EHA Annual Meeting

Consensus EPS estimates upgraded to US$2.90 loss, revenue downgraded

We Think Kymera Therapeutics (NASDAQ:KYMR) Can Easily Afford To Drive Business Growth

Kymera Therapeutics, Inc. Provides Business Highlights and Updates on Its Pipeline of Protein Degraders

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Kymera Therapeutics, Inc., Annual General Meeting, Jun 18, 2024

Price target increased by 7.0% to US$51.07

Kymera Therapeutics, Inc Announces Scientific Presentations At the American Association for Cancer Research 2024 Annual Meeting

Kymera Therapeutics: Advancing Into Phase 2 With Partner Sanofi - I Still Have Faith

Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs At the American Academy of Dermatology Annual Meeting

New minor risk - Insider selling

Consensus revenue estimates increase by 45%

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Released Earnings Last Week And Analysts Lifted Their Price Target To US$47.43

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Optimistic Investors Push Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Up 39% But Growth Is Lacking

Kymera Therapeutics, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Chief Medical Officer notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Price target increased by 8.3% to US$43.00

Price target increased by 7.3% to US$42.77

New minor risk - Shareholder dilution

Kymera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $274.999133 million.

Kymera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $274.999133 million.

Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Shares Climb 33% But Its Business Is Yet to Catch Up

Kymera Therapeutics, Inc. Presents Interim Results from STAT3 Degrader Phase 1 Clinical Trial at American Society of Hematology Annual Meeting

Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474 (SAR444656)p

Kymera Therapeutics, Inc. Announces Publication of Phase 1 Trial Results for KT-474 (SAR444656), a First-In-Class IRAK4 Degrader, in Nature Medicine

Consensus revenue estimates decrease by 18%, EPS upgraded

Consensus revenue estimates decrease by 12%, EPS upgraded

We Think Kymera Therapeutics (NASDAQ:KYMR) Needs To Drive Business Growth Carefully

Kymera Therapeutics, Inc. to Present New Clinical Data from the Phase 1 Trial of STAT3 Degrader KT-333 at the ASH Annual Meeting

Price target decreased by 16% to US$47.47

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Kymera Therapeutics, Inc. Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474 (SAR444656)

Kymera Therapeutics, Inc. to Report Q3, 2023 Results on Nov 02, 2023

New minor risk - Share price stability

Kymera Therapeutics, Inc. Presents Preclinical Data Demonstrating Activity of MDM2 Degraders in Acute Myeloid Leukemia and Merkel Cell Carcinoma

New major risk - Revenue and earnings growth

Kymera Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Relapsed/Refractory Cutaneous T-Cell Lymphoma and Relapsed/Refractory Peripheral T-Cell Lymphoma

Industry Analysts Just Made A Substantial Upgrade To Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Revenue Forecasts

Consensus revenue estimates increase by 19%

New major risk - Revenue and earnings growth

Here's Why We're Not Too Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Situation

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Kymera Therapeutics, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Kymera Therapeutics, Inc.(NasdaqGM:KYMR) dropped from Russell Small Cap Comp Value Index

Kymera Therapeutics’ STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413 Demonstrate Desired Target Knockdown and Safety with Continued Dose Escalation in Ongoing Phase I Clinical Trials

Kymera Therapeutics Announces Updated Clinical Data from the Phase 1 Trials of STAT3 Degrader KT-333 and IRAKIMiD Degrader KT-413

Kymera Therapeutics, Inc. Presents Data Demonstrating Superior Efficacy of Kt-253, A Potent and Selective Heterobifunctional Mdm2 Degrader

Kymera Appoints Jeremy Chadwick as Chief Operating Officer

Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Share Price Not Quite Adding Up

Kymera Therapeutics, Inc. Presents Clinical Data from the Phase 1 Trial of Irak4 Degrader, KT-474 (Sar444656), At the European Academy of Dermatology and Venereology Symposium

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind